Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Non-drug therapy costs for people with MS in Austria can be high, averaging €136 per month, according to a study.

Columnist Desiree Lama shares what she wishes she'd been told after her diagnosis of multiple sclerosis at age 17.

The researchers suggest clinicians might tailor their approach to account for Asian Americans' younger average age when they ...

Columnist Ahna Crum may not have a green thumb, but her plants have taught her valuable lessons about how to thrive in life ...

MS Canada is calling on everyone across Canada to join one of the many MS Bike rides to help raise funds for multiple ...